



מדינת ישראל
STATE OF ISRAEL


REC'D 31 OCT 2003
WIPO PCT

Ministry of Justice
Patent Office

משרד המשפטים
לשכת הפטנטים

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
of which particulars are
specified on the first page
of the annex.

זאת להעודה כי
ריצופים בזו העתקים
נכונים של המטמכים
שהופקרו לבקשתה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.



**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

נחתא
Certified

לשימוש הלשכה
For Office Use

מספר : 151955
Number :
תאריך : 6-09-2002 Date
חובקם/נוחה Ante/Post-dated

15037/bc/02

בקשה לפטנט
Application for Patent

אני, (**שם, המבקש, מענו ולגבי גוף מאוגד - מקום התאגדותה**)
I (Name and address of applicant, and in case of body corporate - place of incorporation)

**YISSUM RESEARCH DEVELOPMENT COMPANY OF THE
HEBREW UNIVERSITY OF JERUSALEM
Jabotinsky 46, Jerusalem**

- (75%) יישום חברה לפתוח ומחבר ש-
האוניברסיטה העברית בירושלים
ז'בוטינסקי, 46, ירושלים

**B.G.U NEGEV TECHNOLOGIES AND APPLICATIONS Ltd.,
P.O. Box 653, Beer Sheva 84105**

- (25%) ב.ג. נגב טכנולוגיות ויישומים בע"מ
ת.ד. 84105, באר שבע 653

owner, by virtue of

the Law

הדין

בעל אמצעה מכת

1 invention the title of which is
(Hebrew)

שםה הוא
(בעברית)


שימוש באפלוטיפ של רגישות למחלות פרקינסון בסריקות גנטיות

(Ենգլիական) (Անգլերեն)

PARKINSON'S DISEASE-SUSCEPTIBILITY HAPLOTYPE AS A TOOL FOR GENETIC SCREENING

I hereby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי ינתן עלייה פטנט

Application of Division מבקשת פטנט from Application No. מס' מיום Dated מס' מיום	Application for Patent Addition לבקשתן/לפטנט to Patent/Appl. No. מס' מיום Dated מס' מיום
יפו כה : כלל/ מיחוץ נציג באה/ עוד יגיש P.O.A.: general/ individual -attached/to be filed later filed in case 126263, 104830	
המعن למיסרת מסמכים בישראל Address for Service in Israel LUZZATTO & LUZZATTO P.O. Box 5352 Beer-Sheva 84152	
לוצאתו את לוצאתו ת.ד. 5352 באර שבע 84152	
חתימת המבקש  Mr. Luzzatto ב"כ המבקש LUZZATTO & LUZZATTO ATTORNEYS FOR APPLICANTS	

דרישת דין קדימה Priority Claim			
מספר/סימן Number/Mark	תאריך Date	!	מדינת האgod Convention Country

היום 25 בחודש ספטמבר לשנת 2000 של השנה
This day 25 of the month September in the year 2000 of the year

טופס זה, כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשתה, הינו אישור להגשת הבקשה שפרטיה רשומים לעיל.
his form, impressed with the Seal of the Patent Office and indicating the number and date of filling, certifies the filing of the application
.e particulars of which are set out above.

• מהק את המיותר •
whatever is inapplicable

15037/bc/02

שימוש בהaplוטיפ של רגישות למחלת פרקינסון בSCREENING גנטיות

PARKINSON'S DISEASE-SUSCEPTIBILITY HAPLOTYPE AS A TOOL FOR GENETIC SCREENING

Field of the Invention

The present invention relates to a genetic predisposition to Parkinson's Disease, involving a haplotype found on Chromosome 7.

Background of the Invention

All publications mentioned throughout this application are fully incorporated herein by reference, including all references cited therein.

Parkinson's Disease (PD) is a late-onset, progressive neurodegenerative disorder consisting of a variable combination of clinical symptoms: resting tremor, muscular rigidity, bradykinesia and a characteristic disturbance in gait and posture. The disease generally commences in the middle or late life and leads to progressive disability with time. It has an equal sex distribution, occurs in all ethnic groups, and has a prevalence of 1-2 per 1000 in the general population [Lang A.E. and Lozano A.M. (1998) *N. Engl. J. Med.* 339:1044-1053, 1130-1143; Aminoff M.J. (2001) Parkinson's disease and other extrapyramidal disorders. In: Braunwald E. *et al.* (eds) *Harrison's principles of internal medicine*. McGraw Hill, pp.2399-2406].

Pathologically, PD is characterized by the progressive death of selected populations of neurons, especially dopaminergic neurons of the pars compacta of the substantia nigra. Other regions, such as the aminergic brain-stem nuclei (both catecholaminergic and serotoninergic), the cholinergic nucleus basalis of Meynert, hypothalamic neurons, and small cortical neurons (particularly in the cingulate gyrus and entorhinal cortex), as well as the olfactory bulb, sympathetic ganglia, and parasympathetic neurons in the gut, may also suffer neuronal loss. Neuronal degeneration within the pars compacta of the substantia nigra leads to a reduction in dopamine levels within the striatum, and especially the Putamen, thereby accounting for the typical akinesia and rigidity seen in the disease. Other pathological features include the

appearance of Lewy neuritis as well as eosinophilic hyaline inclusions called Lewy bodies.

Neuronal death may be caused by a variety of possible mechanisms, for instance mitochondrial dysfunction [Vingerhoets F.J.G., *et al.* (1994) *Ann. Neurol.* 36:765-70], the metabolism of oxidants produced in the course of neural metabolism [Jenner P. and Olanow C.W. (1996) *Neurology*, 47(Suppl 3): S161-S170], possible deficiencies in neurotrophic factors, resulting in decreased neural repair and leading to degradation of dopaminergic cells [Aminoff (2001) *id ibid.*], immune factors found where there is progressing neuronal loss, as seen through an increase in cytokines such as interleukin-1 and tumor necrosis factor α in the pars compacta of the substantia nigra in parkinsonian patients [Lang A.E. and Lozano A.M. (1998) *N. Engl. J. Med.* 339:1044-1053, 1130-1143].

In addition, various environmental factors are linked to the occurrence of Parkinson's disease. Living in rural regions was found to be associated with a higher risk of Parkinson's disease, as well as a possible connection with exposure to herbicides, pesticides and well water [Betarbet, R. *et al.* (2000) *Nature Neurosci.* 3:1301-6; Menegon, A. *et al.* (1998) *Lancet* 352:1344-6.]

Age appears to be the most significant risk factor for Parkinson's disease, with an increase in prevalence up to 1-2 per 100 in people over the age of 65. Curiously, smoking is an environmental factor with a negative risk, since it has been found that the odds ratio for ever having smoked in Parkinson's patients, as compared with general population, is 0.5 [Tanner C.M. *et al.* (1997) *Neurology*, 48(Suppl):A333; Le Couteur D.G. *et al.*, (2002) *Rev. Environ. Health* 17:51-64].

Genetic factors of Parkinson's disease

Genetic factors have proven to have an important role in Parkinson's disease.

Studies conducted with monozygotic twins showed a higher incidence of Parkinson's disease in one twin with young onset disease [Tanner C.M. (1997) *id ibid.*]. In Iceland, a study was conducted in 772 Parkinson patients as well as 1000 independently drawn, matched control subjects [Sveinbjornsdottir S. *et al.* (2000) *N. Engl. J. Med.* 343:1765-1770]. For each patient, the genealogical proximity from another patient of the same family was evaluated and a kinship coefficient obtained, demonstrating the genetic relationship between two patients, or the probability that a randomly selected allele from each member of a pair of subjects was from a common ancestor. The results showed that for the 772 Parkinson patients, the average kinship coefficient was 2.7 (when multiplied by 10,000) as compared with 2.0 ± 0.1 (mean \pm SD) in the control population (p value <0.001), thereby strengthening the notion that Parkinson's disease has a familial component.

Furthermore, a higher risk ratio of Parkinson's disease for relatives of affected patients has also been reported. It was shown that relatives of patients were at a higher risk of suffering from Parkinson's disease than the general population. This was most pronounced in siblings (p value <0.001) and first degree relatives (p value=0.001), than other relatives. Spouses showed no significant risk, thereby indicating the unlikelihood of the possibility that a shared environmental factor, late in life, accounts for Parkinson's disease, though the higher risk to siblings than to offspring indicates towards a possible environmental cause in early life [Tanner C.M. (1997) *id ibid.*; Jenner P.M. and Olanow C.W. (1996) *Neurology* 47:Suppl 3:S161-S170].

Several genes have been mapped that cause inherited monogenic forms of the disease. These genes are found to play a role in the formation of various proteins, such as α -synuclein and parkin, or to be linked to cellular processes as the electron transport chain in the mitochondria. Mutations in these different genes may cause varied probabilities of being afflicted by Parkinson's

disease, as well as affecting its phenotype. However, these mutations are apparently responsible only for a small number of families. As of yet, the genetic basis for the sporadic form of the disease remains unknown.

Mutations in the gene for α -synuclein

The gene encoding the α -synuclein protein is located on the long arm of human chromosome 4. The gene encodes a small (14kDa) highly conserved protein, found abundantly in many brain regions. This protein appears to take part in synaptic development, function, and plasticity.

Two point mutations in the gene were found in families of Parkinson's disease patients. Determination of the exact mutations revealed, in one Italian family, a single base mutation in position 209 from guanine to adenine (G209A) which resulted in an alanine to threonine substitution at position 53 (Ala53Thr) [Polymeropoulos M.H. et al. (1997) *Science*, 276:2045-47]. The second case involved two Greek families with another base change which resulted in an alanine to proline substitution at position 30 (Ala30Pro) [Kruger R. et al. (1998) *Nat. Genet.* 18(2):106-8].

Structurally, the wild type, as well as these mutant forms, are found in an unfolded conformation under physiological conditions. When the protein goes into a partially folded intermediate, a nucleation-dependent mechanism occurs, resulting in the formation of fibrils.

However, comparing the amino acid sequence of the wild type and mutant proteins revealed that the mutant forms differed from the wild type in their probability to aggregate. Both mutations showed a decrease in the probability to form a α -helix in the N-terminal regions, and an increased propensity to form β -sheets than the wild type protein. These structural changes, although not affecting the monomeric protein structure, have a direct influence on the increased tendency of the mutant proteins to form aggregates and fibrils,

leading to the formation of Lewy bodies typically found in the disease [Spillantini M.G. et al. (1997) *Nature*, 388:839-40], thereby providing support for a direct role of α -synuclein aggregation in the etiology of Parkinson's disease.

PARK 2 - Autosomal Recessive Juvenile Parkinsonism (AR-JP)

A second form of inherited Parkinson's disease is linked to a genetic locus mapped to the long arm of chromosome 6, the *parkin* gene. Clinically, these patients show an early age of onset, levodopa responsiveness, diurnal fluctuations of symptoms (becoming worse later in the day), as well as early and severe motor fluctuations and dyskinesia, with no evidence of Lewy bodies within the brain tissue. A recent work attempted to identify various mutations in the *parkin* gene [Lucking C.B. (2000) *N. Engl. J. Med.* 342:1560-7]. 73 families (152 patients with Parkinson's disease and 53 unaffected relatives) that met the following criteria were examined: symptoms of parkinsonism which appeared before the age of 45, symptoms reduced by at least 30% by levodopa, a mode of inheritance compatible with autosomal recessive transmission, absence of extensor plantar reflexes, ophthalmoplegia, early dementia, or early autonomic failure. The families were gathered from countries around the globe. In addition, 100 patients with isolated Parkinson's disease were selected according to the same criteria. The screening for mutations was performed using a semiquantitative PCR assay for the detection of rearrangement of *parkin* exons. 19 different homozygous and heterozygous exon rearrangements were found, as well as 16 different point mutations, indicating that among patients with the autosomal recessive juvenile parkinsonism (AR-JP) variant, mutations in the *parkin* gene are frequent and varied. Clinical symptoms were also gathered from these patients and compared to identify any clinical distinctions. The patients with *parkin* mutations presented different symptoms from the isolated Parkinson's patients. No differences were found between patients bearing different mutations.

Through the use of semiquantitative PCR, mutations within the *parkin* gene were identified. The majority of mutations (70%) was found in patients suffering from AR-JP, thus pointing towards a link between the different mutations in the *parkin* gene and the appearance of the AR-JP variant of Parkinson's disease [Kitada T. et al. (1998) *Nature* 392:605-8]. However, although these patients showed early onset, no unique clinical signs were found to distinguish these patients from patients suffering from other causes of Parkinson's disease.

Mitochondrial electron transport chain and Parkinson's disease

Loss of electron transport chain activity is noted in various tissues in Parkinson's patients [Parker W.D. and Swerdlow R.H. (1998) *Am. J. Hum. Genet.* 62:758-62]. This biochemical defect is found in many tissues, including: platelets, lymphocytes, brain, muscle, and fibroblasts. Evidence using immunoblot studies has demonstrated that a disruption of NADH ubiquinone oxidoreductase (complex I) subunits may be the cause of loss of mitochondrial activity. Furthermore, toxins such as the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) derived toxic metabolite MPP⁺ [Vays I. et al. (1986) *J. Neurochem.* 46:1501-7], together with various neuroleptic medications (haloperidol, chloropromazine, thiothixene) [Burkhardt C. et al. (1993) *Ann. Neurol.* 33:512-7], which all produce Parkinson symptoms, have been shown to inhibit complex I activity in animal models. Therefore, disruption of normal mitochondrial activity may play a role in the appearance of Parkinson's disease.

Once complex I activity is decreased, the entire electron transport chain function may be perturbed, resulting in several consequences, a decrease in adenosine triphosphate (ATP) synthesis, followed by an accumulation of reactive oxygen-species (ROS) and oxidative stress within the cell. These effects were examined in immortalized human cell lines, depleted of

mitochondrial DNA (mtDNA) by culturing for 3-4 months with ethidium bromide. mtDNA was reintroduced to these cells from platelets of Parkinson's disease patients (creating PD hybrid cells), resulting in an increase in ROS production when compared with controls [Cassarino D.S. *et al.* (1997) *Biochim. Biophys. Acta*, 1362:77-86]. These changes may have a role in initiating apoptotic cell death within the afflicted regions of the brain. Moreover, such cells showed an increased sensitivity to MPP⁺ when compared to control cells, leading to apoptotic cell death. Thus, a possible interaction between a genetic abnormality and an environmental agent may cause the disease phenotype.

Interestingly, an epidemiological study showed that in families where Parkinson's disease was present in parents and children, the disease seemed to be transmitted by the maternal lineage [Wooten G.F. *et al.* (1997) *Ann. Neurol.* 41:265-8]. Children with a mother who was ill showed an earlier onset of the disease when compared with their parent ($p<0.001$), while patients with a father who had the disease showed no significant difference in the age of onset. The maternal transmission might be associated with a mitochondrial defect.

Paraoxonase 1 (PON1)

The *PON1* gene maps to chromosome 7q21.34 and it is localized 10,000 Kb downstream from the *ACHE* gene (Fig. 1). The *PON* gene family includes two or more genes of unknown function.

The gene product, PON1, is an aryldialkylphosphatase also known as paraoxonase, which hydrolyzes soman, sarin, paraoxon, diazinon, and other organophosphate (OP) substrates. PON1 is a glycoprotein associated with a subset of HDL molecules, which is produced and secreted in the liver, and exists in many tissues, particularly liver, kidney, small intestine and serum. This enzyme detoxifies OPs by hydrolyzing them, and prevents lipoxidation

of LDL and HDL [Mackness B. et al. (1998) *Gen. Pharmac.* 31, 329-336]. PON1 serum levels may vary by up to 40-fold from one individual to another.

Two coding region and five promoter polymorphisms are known in the *PON1* gene (Fig. 2) (Brophy V. H. et al. (2001a) *Pharmacogenetics* 11:77-84; Brophy et al. (2001b) *Am. J. Hum. Genet.* 68:1428-1436]. In the coding region, the two polymorphisms are point mutations that result in amino acid changes. One is at amino acid position 54, L54M (CTG into ATG), while the second is at amino acid position 192, Q192R (CAA into CGA). Interestingly, the 54L allele is linked to the 192R allele [Akhmedova S.N. et al. (2001) *J. Neurol. Sci.* 184:179].

The PON1 192R alloenzyme is more active with the following OPs than is the alloenzyme paraoxon, methylparaoxon, chlorothion EPN oxon and armin. The 192Q variant affords the carrier better protection against the following OPs: diazoxon, sarin and soman. While both alloenzymes hydrolyze the following substrates equally well: phenyl acetate, chlorpyrifos oxon and naphtylacetate-2 [Costa L.G. et al. (1999) *Chem. Biol. Interact.* :119-120, 429-438; Mackness, B. et al. (1998) *Gen. Pharmacol.* 31:329-336].

The polymorphism at position 192 affects mRNA and protein levels, but not biochemical properties. The 192M variant is associated with low serum levels, and thus affords lower protection to xenobiotics [Costa et al. (1999) ibid.; Kondo and Yamamoto (1998) *supra*].

PON1 promoter polymorphisms

-108 C/T This polymorphism occurs at a putative SP1 binding site. The C variant produces more enzyme than the T variant (Brophy et al. (2001s) ibid.; Brophy et al. (2001b) ibid.].

15037/bc/02

-909 G/C This variant has no major effect on gene expression, except when it is linked to other polymorphisms.

-162 A/G The A variant promotes higher transcriptional activities than the G variant. It is localized in a putative NF1 binding site.

PON1 status is defined as the combination of the genotype and the phenotype, the latter being affected by a high fat diet and exposure to xenobiotics - which reduce PON1 expression regardless of the genotype. Species with low PON1 activities display higher OP sensitivity [Costa L.G. *et al.* (1987) Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In: Costa L.G. (eds.) *Toxicology of pesticides: experimental, clinical and regulatory perspectives*. Springer-Verlag, Heidelberg, pp.263-266]. Accordingly, *PON1*-/- knockout mice are five- to ten-fold more sensitive to the anti-ChEs diazoxon and chlorpyrifos oxon than wildtype mice [Furlong C.E. *et al.* (1998) *Neurotoxicology* 19(4-5):645-50; Costa L.G. *et al.* (1999) *id ibid.*]. PON1 192R carriers have a higher risk for coronary arterial disease CAD [Nassar B.A. *et al.* (2002) *Clin. Biochem.* 5:205-209].

The PON1 alleles show different distributions in specific ethnic groups. No study has yet been performed in the Israeli population. A study comparing Chinese/Japanese and Caucasian populations showed the following incidence of polymorphism (Table 1) [Wang and Liu (2000) *supra*]:

Table 1

Chinese/Japanese	Caucasian	PON1 Polymorphism
	0.46	-909G
	0.54	-909C
0.10	0.23	-162A
0.90	0.77	-162G
0.48	0.50	-108C
0.52	0.50	-108T
0.94	0.64	55L
0.06	0.36	55M
0.40	0.73	192Q
0.60	0.27	192R

Other population studies have demonstrated the following results (Table 2):

Table 2

Connection between PD and PON1	Ethnic group	Reference
No link	Caucasian	(Taylor <i>et al.</i> , 2000) ^b
No link	Chinese	(Wang <i>et al.</i> , 2000) ^c
Higher PON1 192R incidence in PD patients. R homozygotes show 1.6 ratio of increased risk. ^a	Japanese	(Kondo <i>et al.</i> , 1998) ^d
Higher PON1 55M incidence in PD patients, with 2.19 odds ratio. Yet higher PON1 55M incidence in PD patients, with 2.19 odds ratio. Yet higher PON1 55M in PD patients with <51% early onset. Odds ratio, 5.15. Yet higher risk for those homozygous for the 192Q allele.	Russian	(Akhmedova <i>et al.</i> , 2001) ^e

^aThe risk ratio is the frequency of PD among the population under study compared to the frequency in a control population.

^b[Taylor M.C. et al. (2000) *J. Neural Transm.* 107:979-983]

^c[Wang J. and Liu Z. (2000) *Mov Disord* 15:1265-1267]

^d[Kondo I. and Yamamoto M. (1998) *Brain Res* 806:271-273]

^e[Akhmedova S.N. et al. (2001) *J. Neurol. Sci.* 184:179-182]

PON1 polymorphisms and the Gulf War syndrome

In a study of Gulf War veterans, the R allele appeared more frequently in those affected by GWS than in those unaffected [Haley R.W. et al. (1999) *Toxicol. Appl. Pharmacol.* 157:227-233]. PON1 192Q carriers displayed lower PON1 serum activities in sick veterans when compared to healthy veterans.

PON1 and Parkinson's disease

PON1 acts in the blood stream as a hydrolyser of various toxins which escape hepatic detoxification. The two *PON1* polymorphisms in the coding region, an arginine to glutamine exchange at position 192 (Arg192Gln), and a methionine to leucine at position 54 (Leu54Met), influence the ability of PON1 to hydrolyze toxins, and may intensify the effects of pollutants, organophosphates and other environmental chemicals in the development of Parkinson's disease.

In a study to determine the association between the Leu54Met polymorphism and Parkinson's disease [Akhmedova S.N. et al. (2001) *id ibid.*], 117 unrelated idiopathic Parkinson's disease patients were analyzed. When compared to the distribution of the polymorphism in the general population, it was found that the Parkinson's Disease patients presented a higher incidence of the Leu54Met allele ($p<0.003$). Therefore, it seems that there is an association between the presence of the Leu54Met polymorphism and an increased risk of Parkinson's disease. The change in the activity of the enzyme, due to the polymorphism, does not ensure that one develops the disease, but it may indicate a higher

sensitivity towards various chemicals and toxins which might trigger the disorder.

To conclude, it can be inferred that Parkinson's disease is manifested in a variety of forms, varying from the early onset disease with no presence of Lewy bodies, to the "classic" late onset manifestation. The occurrence of the disorder is influenced by many factors, including environmental, such as exposure to various chemicals (MPTP, neuroleptic drugs, organophosphates, and such), rural living (which might also be connected to an increase in exposure to such compounds) or occupational, as well as genetic predisposition. At least three genes induce increased risk for PD, while exposure to xenobiotics acts as a direct cause of PD in sporadic cases [Kaufer D. and Soreq H. (1999) *Curr. Opin. Neurol.* 12:739-743]. The relationship between the two causes is yet unknown.

ACHE

Acetylcholinesterase (AChE), a type B carboxylesterase, hydrolyses and inactivates acetylcholine (ACh). Changes in the level and mode of *AChE* gene expression are revealing indicators of alteration in cholinergic neurotransmission. For example, both acute psychological stress and exposure to organophosphate and carbamate AChE inhibitors (anti-AChEs) were found to induce rapid, yet long-lasting transcriptional AChE activation that was accompanied by a splicing shift, from the major AChE-S variant to the rare AChE-R mRNA and protein [Kaufer *et al.* (1998) *Nature* 393:373-7; Soreq, H. and Seidman, S. (2001) *Reviews in Neuroscience* 2, 294-302].

The upstream promoter of the *ACHE* gene includes two mutations, one of which confer overproduction and hypersensitivity to anti-ChEs [Shapira M. *et al.* (2000) *Hum. Mol. Genet.* 9:1273-1281] (Fig.3). Carriers of this *ACHE* promoter deletion express higher blood cell AChE levels and higher AChE activity (twice normal) in immortalized lymphocytes [Shapira (2001)].

Transgenic human AChE-over-expressing mice suffer hypersensitivity to both carbamate and OP inhibitors and survive for a shorter time after injection of a lethal dose of diisopropylfluorophosphonate (DFP) than mice of the parent strain. Unlike normal mice, they are unable to induce AChE-R over-production following exposure, which contributes to their hypersensitivity.

ACHE haplotypes:

The different polymorphisms in the *ACHE* locus together form a haplotype with internal linkage that confers a common heritage. H332N (Asp for His) is the serological marker of the Yt^b blood group, while P446 is a silent mutation (Fig. 4). These two mutations were reported to be 100% linked in the US population [Bartels et al. (1993)]. In a later study, 80% linkage was shown for the promoter deletion with H332N [Shapira et al. (2001)], linking these 3 sites.

ACHE and Parkinson's Disease

Exposure, even sub-acute, to xenobiotics may induce a toxic response of the intestine, the immune system, muscle or brain, and alter metabolic activities to the extent that longevity is affected, all depending on the genotype of the patient, type of exposure, and level of the toxin's penetrance.

Some of these xenobiotics are anti-cholinesterases, like carbamates and organophosphates (OPs), which block acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as other gene products, and are known to increase the risk of several diseases, thus shortening life-expectancy. Some examples of affected enzymes are the 'atypical' BuChE, which bears the D70G mutation that confers acute sensitivity to anti-cholinesterases [Loewenstein-Lichtenstein Y. et al. (1995) *Nat. Med.* 1:1225-1226; Neville L. F. et al. (1990) *J. Biol. Chem.* 265: 20735-20738], and, as mentioned previously, PON1 and its polymorphic variants.

Less dramatic differences in BuChE properties than those conferred by the "atypical" mutation are conferred by the K-variant, which involves an A539T substitution in BuChE and reduces the catalytic activity by 30% [Bartels C.F. et al. (1992) *Am. J. Hum. Genet.* 50:1086-1103]. This variant has an allele frequency of 12% in the Caucasian population. This incidence is therefore high enough to test for the association of BuChE-K with the risk of developing specific diseases. This was first attempted with regard to Alzheimer's disease (AD), where some [Lehmann D.J. et al. (1997) *Hum. Mol. Genet.* 6:1933-1936; Lehmann D.J. (2000) *Hum. Genet.* 106:447-452.] but not all [Brindle N. et al. (1998) *Hum. Mol. Genet.* 7:933-935] reported an increased risk for late-onset AD in BuChE-K carriers. Yet more recently, BuChE-K's association with coronary artery disease (CAD) was tested. [Nassar (2002) *id ibid.*] The outcome of that study suggested an increased risk for CAD in BuChE-K carriers, as patients with early-onset CAD had greater BuChE-K frequency than patients with the late-onset disease. Although that difference was not significant, patients with early-onset CAD were significantly more likely to carry both BuChE-K and the ε4 allele of apolipoprotein ε, which by itself increases the risk for early-onset CAD [Premkumar D.R. (1996) *Am. J. Pathol.* 148:2083-2095]. The hypothesis was advanced that this reflects additive risks from these polymorphisms for the development of premature CAD [Nassar (2002) *id ibid.*]. The current evidence thus suggests a synergism between the effects of BuChE and apolipoprotein ε, which has been proposed to protect both the cardiovascular system and the CNS from oxidative stress, and its ε4 variant of apolipoprotein ε is apparently less effective in this function [Nassar B.A. et al. (1999) *Clin. Biochem.* 32:275- 282], leading to enhanced risk for both AD and CAD. BuChE has indeed been reported to interact with lipoproteins and alter their metabolism. [Abbott C.A. et al. (1993) *Clin. Sci. (Lond)* 85:77-81]. Therefore, the combination of two variants with insufficient protective capacities may cause more significant cumulative damage to the cardiovascular and nervous systems. The related effect of paraoxonase polymorphism AChE and apolipoprotein ε4 are not the only proteins, the functions

of which intersect that of BuChE. The phosphatase,paraoxonase 1 (PON1), may also participate in detoxification of organophosphates [Masson P. et al. (1998) *J. Physiol. Paris* 92:357-362]. It also prevents lipoxidation in LDL and HDL. [Mackness B. (1998) id ibid.]. There are two known polymorphisms in the coding region of the PON1 gene that affect its activity and which lead to amino acid substitutions,L55M and Q192R [Mackness et al. (1998) id ibid.]. Additionally, there are three promoter polymorphisms that modulate PON1 production. Whatever the genetic basis of the effect, PON1 serum levels may vary up to 40-fold from one individual to another. For this gene, as well, there are very different frequencies of the polymorphisms from one ethnic group to another [Diepgen T.L. (1986) *Arch. Toxicol. Suppl.* 9:154-158]. A decreased PON1 level obviously places an additional burden on the detoxifying function of BuChE,especially under the stress of organophosphate exposure. However, although the PON1 R allele has been reported to selectively increase the risk for CAD [Adkins S. et al. (1993) *Am. J Hum. Genet.* 52:598-608],, there appeared to be no interaction between BuChE-K and PON1-R in increasing this risk [Nassar (2002) id ibid.]. It is therefore possible that BuChE-PON1 interactions would be relevant only in those diseases that develop following OP exposure, but not in every case of CAD.

The present invention stems from the inventors' findings that, amongst the *PON1* and the *ACHE* polymorphisms, there seems to be a tendency of certain alleles to segregate together. Interestingly, the resulting combination of *PON1* and *ACHE* alleles and the incidence of PD in the carriers suggests that there is an haplotype that is more susceptible to PD. Hence, the present invention has as an object utilizing such haplotype as a diagnostic tool the risk of PD individually and for the population of interest. This and other objects of the invention will be elaborated on as the description proceeds.

Summary of the Invention

The present invention relates to the use of the "Parkinson Disease (PD)-susceptibility haplotype", as herein defined, as a tool for the prediction of PD risk and severity in a population and/or an individual.

In particular, the invention relates to a method of predicting genetic predisposition to PD, by the following screening method:

- (a) obtaining a blood sample from an individual to be screened; and
- (b) analyzing the DNA from said blood sample for the presence or absence of the "PD-susceptibility haplotype" as herein defined, by appropriate means;

whereby the presence of the "PD-susceptibility haplotype" indicates a higher predisposition to PD, and the absence of the "PD-susceptibility haplotype" indicates a lower predisposition to PD, compared to a control.

In yet a further aspect, the invention relates to a kit for screening for genetic predisposition which essentially comprises means for collecting blood samples and for isolating DNA therefrom and reagents for detecting the presence of the said "PD-susceptibility haplotype".

The invention will be described in more detail on hand of the following Figures.

Brief description of the Figures

Figure 1 The PD susceptibility locus on Chromosome 7. Spanning the region of 9_{21.3} - 9₂₂ on the long arm of chromosome 7, this locus includes the *PON*, *ACHE*, *ARS*, and *PLX* genes [Grant et al. (2001)].

Figure 2 *PON1* gene polymorphisms.

Figure 3 Schematic of the *AChE* gene.

Figure 4 AChE gene polymorphisms

- (a) Incidence of the deletion mutation on the HNF3 binding site on the AChE promoter region. The frequency in the Israeli population is ten-fold higher, when compared to the U.S.A. This frequency is based on our screening of North – Carolina volunteers as compared with Israelis [Shapira (2000) *supra*]. It is further compatible with the 80% linkage which was found between the HNF₃ mutation and the H322N polymorphism in Israelis [Shapira (2000) *supra*] and with the relatively high incidence of this H322N polymorphism, which determines the Ytb blood group in middle-east population [Ehrlich et al., (1994) *Genomics*]. The linkage between the different polymorphisms on this locus extends throughout the ACHE site, as Bartels et al. [(1993) *supra*] showed 100% linkage between the “silent” P446 polymorphism. Thus, the HNF₃ deletion, the H322N mutation and the silent P446 polymorphism are all linked together, creating a haplotype.
- (b) AChE polymorphisms, described by Shapira (2000) and Bartels (1993) [Shapira M. et al. (2000) *Hum. Mol. Genet.* 9:1273-1281; Bartels C.F. et al. (1993) *J. Hum. Genet.* 52:928-936].

Figure 5 BuChE activity in urban and rural PD patients.

The activity of BuChE in the group of exposed is lower than in non-exposed subjects, irrespective of the presence of the mutation. The figure shows specific BuChE activity in nmoles/min/mg protein. This proves exposure risk in the examined population.

Figure 6 Serum BuChE activity

Comparison of BuChE activity in urban and rural groups, showing lower BuChE activity in the rural PD group compared to urban. The figure shows specific BuChE activity in nmoles/min/mg protein. No significant differences were found between carriers (carr) and non-carriers (wt). Numbers in each column indicate sample size in each group. This proves validity of comparison between Rural and Urban populations.

Figure 7 Serum AChE activity

Comparison of AChE activity in urban and rural groups. The figure shows specific AChE activity in nmoles/min/mg protein. Lower AChE activity in the rural compared to urban. No significant differences were found between carriers (carr) and non-carriers (wt). Numbers in each block indicate sample size in each group. $p=0.03$.

Figure 8 AChE activity in PD patients

AChE activity in PD patients with mutations is lower than without mutations. The differences are statistically significant, $p=0.003$.

Figure 9 BuChE activity in PD patients

BuChE activity in PD patients with or without mutations is lower than rural healthy individuals.

Figure 10 The *ACHE* promoter polymorphism in various age groups and health conditions in Israel.

Figure 11 Percent frequency of HNF mutation.

Figure 12 The *PON1-ACHE* polymorphism pattern.

Detailed Description of the Invention

The present invention relates to a haplotype present on human chromosome 7, which the inventors have found to be directly linked to a higher susceptibility to develop Parkinson's Disease (PD).

This haplotype is comprised by the presence of *PON1* alleles L54M, Q192R and *ACHE* alleles del HNF3, H332N, P446 in linkage, demonstrated by an apparent segregation frequency of 100% in PD patients, which is significantly different from the expected frequency of segregation for unlinked alleles of 5%. Thus, the inventors named this the "Parkinson Disease (PD)-susceptibility haplotype" which is associated with increased risk to develop this neurodegenerative disease, especially following exposure to anticholinesterases.

Thus, in a first aspect, the present invention relates to the use of the "PD-susceptibility haplotype" as a tool for the prediction of PD risk and severity in a population and/or an individual.

As shown in the Examples, the PD-susceptibility haplotype is present in 9% of the examined PD patients. It is characterized by having alleles L54M and Q192R of *PON1* segregating in linkage with alleles del HNF₃ AND H332N AND P446 of *AChE*. This is not a random event since the two genes are 10 megabase apart, indicating independent recombination.

In a second aspect, the invention relates to a diagnostic method of predicting susceptibility to PD, based on the detection of the "PD-susceptibility haplotype" in an individual.

The classical method of detection of these polymorphisms, restriction fragment length polymorphism (RFLP), is being replaced by methods that utilize the power of PCR amplification together with the enhanced size resolution by electrophoresis of labeled PCR products on thin polyacrylamide gels. When these techniques are combined in the automated sequencer, accurate sizing and quantification is possible. This technique employs the use of a forward primer, 5'-labeled with the fluorescent dye 6-FAM, and an unlabeled reverse primer in a PCR reaction. The resulting PCR product has a forward primer-derived strand that is labeled and therefore detectable in the ABI PRISM 3700 DNA Analyzer. The automated machine is capable of simultaneously detecting up to four different fluorescent dyes, this allows the use of a fluorescent internal size standard that can run in the same lane as the PCR sample. The use of this internal size standard overcomes lane to lane variation and allows consistent quantification and sizing of PCR products in different lanes.

Single Nucleotide Polymorphism

Detection of single base variations in DNA in the form of a point mutation or single nucleotide polymorphisms (SNP) can serve as a powerful genetic mapping tool. These variations are used to provide insight into population dynamics or pharmacogenomics or to signify phenotypic consequence.

Single nucleotide primer extension is a straightforward method for validation or comparative genotyping of known SNPs and point mutations. This technique permits exact base identity determination of a polymorphic locus without direct sequencing. The information potential of a base change can be effectively determined using the SNaPshot™ ddNTP Primer Extension™ method, which is ideal for locus validation and subsequent screening of individuals (genotyping).

The 3' terminus of an unlabeled oligonucleotide primer is extended by a single fluorophore-labeled ddNTP. Because the primer is designed to anneal directly adjacent to the variant base of interest and the reaction does not include dNTPs, incorporation occurs only at a single site. Each of the four possible dye labeled terminators in a SNaPshot ddNTP primer extension reaction is labeled with a different rhodamine-type fluorescent dye. The labeled primer extension products are detected and analyzed by the ABI PRISM 3700 DNA Analyzer.

Mutation detecting using the LightCycler

The primary advantages of the LightCycler(LC) are to reduce the time taken for PCR amplification reactions, and to perform semi-quantitative and quantitative RT-PCR analyses. The machine achieves this by using a thin-walled glass capillary, heated and cooled in a stream of air. The physical properties of the capillaries permit extremely rapid heating and cooling of samples. This enables PCR cycling through the stages of denaturation, annealing, and extension to occur at a faster rate than conventional PCR

engines. It also eliminates the electrophoretic separation stage of classical PCR.

In addition to being a useful quantitative real-time PCR device, an entirely separate capability of the LC is the detection of known polymorphisms. The LC can measure fluorescence at several different wavelengths. The use of two different fluorescent dyes, fluorescein and Red 640, enables polymorphism detection. The LC can excite fluorescein, which will then emit visible light (fluoresce) at a longer wavelength. If the second dye (Red 640) is in close proximity to the fluorescein, energy transfer occurs, where energy emitted from the excited fluorescein in turn excites the Red 640 dye, which then produces a secondary emission at 640 nm. This energy transfer process is called fluorescence resonance energy transfer (FRET). The LC can detect the specific fluorescence of the Red 640 dye, and can thus measure the level of fluorescein and Red 640 that are in close proximity to one another.

The LC uses this process to detect polymorphisms by attaching each of the two dyes to different hybridization probes. One probe is longer than the other, and is labeled 5' with the Red 640 dye. This probe is complementary to a target sequence that is downstream from the mutation site. The other probe is shorter and is complementary to the wildtype sequence of the mutation site. The shorter probe is labeled 3' with fluorescein. After the target sequence area has been amplified during PCR, a melting curve analysis is performed by gradually increasing the temperature in the capillary. At low temperatures both probes will anneal to the target area, the two dyes will be in close proximity to one another and FRET can occur.

Polymorphism detection using hybridization probes

The LC can detect the resulting fluorescence emission from the Red 640 dye on the longer probe. As the temperature increases, the shorter probe will melt away from the target sequence before the longer probe. At this moment FRET

will no longer occur, and the LC will detect the subsequent drop in fluorescence at 640 nm. Since the shorter probe is complementary to the wildtype target sequence, any mutation in the target sequence will decrease its affinity for the probe, seen as a decrease in the temperature at which the probe and target dissociate. A drop in the temperature at which FRET is lost is thus indicative of a mutation.

In a third aspect, the invention relates to a method of screening for a genetic predisposition to PD, wherein said method involves the steps of:

- (a) obtaining a blood sample from an individual to be screened;
- (b) analyzing the DNA from the blood sample of (a) for the presence or absence of the "PD-susceptibility haplotype" by appropriate means; wherein the presence of the "PD-susceptibility haplotype" indicates a higher predisposition to PD, and the absence of the "PD-susceptibility haplotype" indicates a lower predisposition to PD, compared to a control.

In a last aspect, the invention provides a kit for screening for a genetic predisposition to PD, including

- (a) means for collecting a blood sample;
- (b) reagents for detecting the presence of the "PD-susceptibility haplotype".

Insecticides are detoxified from the organism in three stages. In the first stage, the enzymes p450 (CYP450) and PON1 are involved. In the second stage, the toxic metabolites are conjugated to glutathione transferase, and in the third stage they conjugate to substances that are bound to leave the cell [Ecobichon D. J. and Joy, R.M. (1994) *Pesticide and neurological disease* 2nd. Ed. CRC Press, Boca Raton; Hodgson E. and Lewy, P. E. (1996) *Environ. Health Perspect.* 104:97-106]. Genetic polymorphisms have been found in the genes encoding all these enzymes [e.g. Menegon (1998) id ibid.]. The present study shows a high incidence of the L55M polymorphism of PON1 in PD patients. The high incidence of the ACHE promoter deletion, the ACHE coding sequence Ytb blood group, and the silent mutation on P446 in ACHE suggests the

presence of a defective haplotype in the Mediterranean population, suggesting a genetic basis for the degenerative process triggered by PD.

Disclosed and described, it is to be understood that this invention is not limited to the particular examples, process steps, and materials disclosed herein as such process steps and materials may vary somewhat. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only and not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The following Examples are representative of techniques employed by the inventors in carrying out aspects of the present invention. It should be appreciated that while these techniques are exemplary of preferred embodiments for the practice of the invention, those of skill in the art, in light of the present disclosure, will recognize that numerous modifications can be made without departing from the spirit and intended scope of the invention.

Examples

Experimental Procedures

All the study conducted in accordance with the Provisions of the Committee for Human Trials [Helsinki Committee].

A. Population

Three populations were examined:

1. PD patients without chronic exposure to organophosphates (OPs), i.e. urban residents, n=15.
2. PD patients who used to work in agriculture in the past, and most probably chronically exposed to OPs, i.e. kibbutz residents and farmers, n=15.
3. Non-PD (or any other CNS associated disease) population, age and sex comparable, that worked in agriculture, n=10.

All subjects provided informed consent, filled a medical questionnaire and underwent neurological tests.

B. Anamnesis (medical history) and medical tests

Participants were required to fill in a ethnical data questionnaire including: ethnical background, diseases, past hospitalizations, pharmaceutical treatments, work-related details, residence and also past experiences of exposure to poisons in general and OPs in particular.

C. Collection of blood samples

4 ml of blood was obtained from each participant, and collected in EDTA-containing tubes. The blood sample was divided in 300ml eppendorf tubes and kept at -75°C: One aliquot was centrifuged at 10000 rpm/30 min. at room temperature (RT) for obtaining serum, which was tested for enzymatic activity.

BuChE and AChE activity

BuChE activity in the serum was measured through spectrophotometry, by calculating nmoles of Butyrylcholine (which served as a substrate) degraded/ml serum/time unit as described [Goldsmith J.R. *et al.* (1990) *Arch. Environ. Health* 45: 88-94].

AChE activity in erythrocytes was measured likewise, using Acetylthiocholine as a substrate.

In both BuChE and AChE inhibitors were used in order to inhibit non-specific activity. BW284C51 was used as an inhibitor for AChE, while iso-OMPA was used as an inhibitor for BuChE, both at 5×10^{-5} M.

D. Quantitative measurement of serum protein

Serum protein was measured by the Lowry method (BioRad Laboratories).

E. DNA extraction and detection of polymorphisms

DNA was obtained from whole blood with Puregene isolation kit (Gentra, Minneapolis). DNA from the *AChE* gene promoter region was amplified using PCR, and the nucleotide sequence corresponding to the polymorphism site was tested by ABI 3700 in the DNA analysis service unit at the Hebrew University. Detection of either the A/T substitution, localized in the glucocorticoid receptor binding site, or the 4-nucleotide deletion in the HNF3 binding site, both found in the *AChE* promoter region, were performed by sequence analysis [Shapira *et al.* (2000) *id ibid.*].

F. Haplotype detection

There are two known polymorphisms in the coding region of the *AChE* gene. One results in an asparagine for histidine substitution on position 322 (H322N), also known as Ytb, and the second is a silent mutation on codon 446 (P446). The deletion in the promoter region was found in linkage with the

H322N mutation by Shapira [Shapira *et al.* (2000) *id ibid.*]. In contrast, this same H322N substitution was found by Lockridge [Lockridge O. and Masson P. (2000) *Neurotoxicology* 21:113-26] to be in linkage with the silent mutation in P446. As a result, the four known polymorphs create a variety of haplotypes in the *AChE* gene. The inventors tested whether the carriers of the polymorphic gene inherited it from an ancient common origin, thus as a result of the founder effect, and if so, what is the ethnical origin.

G. Statistical analysis

Accepted statistical analyses were used, such as ANOVA (single factor), Student's t test (paired, two-tailed), SEM, and correlation test.

Example 1

A. Anamnestic data and clinical parameters

The anamnestic data and clinical parameters of the subjects are summarized in Tables 3, 4, and 5.

Table 3: PD patients living in urban area (Group 1)

No.	Age	Sex	Ethnic origin	History of agriculture work	Age of PD onset	Medical history	Familial History P D	Chronic treatment	Rigidity	Bradikinesia	Tremor
1	68	F	Poland	-	62	Essential tremor, HTN	-	Sinemet Gastro	-	-	+
2	85	M	Poland	+	78	CIHD	-	Dopicar Adalat Pergolide	+	+	+
3	85	M	Poland	+	75	CIHD, Bed ridden	-	Dopicar Pergolide	+	+	+
4	72	F	Poland	+	70	HTN	-	Dopicar Sinemet	+	+	+
5	85	F	Germany	+	75	-	-	Dopicar Norvasc	-	-	+
6	88	M	Romania	+	72	Bed ridden dementia	-	Dopicar Phenergan	+	+	-
7	73	M	Hungary	+	63	-	-	-	+	-	-
8	82	F	Romania	+	76	HTN	-	Norvasc Simovil	-	-	+
9	76	F	Poland	-	68	NIDDM	-	Deralin	-	-	+
10	77	M	Brazil	+	67	HTN, Sick sinus syndrome	-	Dopicar Sinemet Cartia	+	+	+
11	76	F	Egypt	+	77	Cataract	-	Lipidal Gastro Vitamin D	-	-	+
12	65	F	Brazil	- color manufacture	62	HTN, Writer cramp	-	Deralin Captopril Fossalan	+	-	+
13	55	M	Brazil	+	52	Meningioma	-	Tegretol Selegiline Evitol	+	+	+
14	68	F	Irak	-	60	Dementia	-	Dopicar	+	+	-
15	69	F	Brazil	-	60	HTN, CVA	-	Eltroxin Aspirin	+	+	+

Table 4: PD patients living in rural area (Group 2)

No.	Age	Sex	Ethnic origin	History of OP exposure	Age of PD onset	Medical history	Familial history of PD	Chronic treatment	Rigid.	Brad	Trem
1.	73	F	Romania	LOW LEVEL EXPOSURE	72	CVA, NIDDM	-	Glibetic Tamoxil	+	+	-
2.	72	F	Romania		71	Bed ridden HTN	-	Dopicar Capoten	+	+	+
3.	76	F	Russia		67	HTN	-	Dopicar Sinemet	-	-	+
4.	67	F	Libian		60	HTN, CIHD	-	Dopicar Ropinirol	+	+	-
5.	52	M	Morocco		40	-	+ sister	Dopicar Sinemet Pergolide	+	+	+
6.	58	M	Argentina		52	-	+ father	Dopicar Sinemet	-	+	+
7.	72	M	Romania		70	HTN	-	Dopicar	+	-	-
8.	74	M	Russia		71	-	-	Dopicar Sinemet	+	+	+
9.	78	F	Russia		72	CIHD	-	Dopicar	+	+	+
10.	65	M	Russia		60	-	-	Dopicar	+	+	+
11.	70	M	Morocco		65	CIHD CVA Bed ridden	-	Dopicar	++	+	-
12.	78	M	Russia		72	HTN CIHD	-	Convertin Normiten Dopicar	+	+	-
13.	77	F	Russia		72	HTN, CVA, NIDDM	-	Glibetic Dopicar Aspirin	+	+	+
14.	68	M	Russia		62	-	+ Sister	Dopicar Pergolide Comtan	+	+	-
15.	84	M	Poland		78	HTN	-	Dopicar Bromocriptine	+	-	+

Table 5: Healthy rural people (Group 3)

No.	Age	Sex	Ethnical origin	Medical history	Permanent treatment	Rigidity	Tremor	Bradi kinesia
1.	73	F	Poland	CIHD	Normiten	-	-	-
2.	78	M	Poland	HTN	Convertin	-	-	-
3.	77	F	Romania	Dermatitis	Ung. Polycutan	-	-	-
4.	74	F	Russia	HTN	Simovil Normiten Cartia	-	-	-
5.	79	F	Russia	PAF	Coumadin	-	-	-
6.	74	F	Romania	HTN	Lasix Verapamil	-	-	-
7.	70	F	Hungary	CIHD	Dilantun Cartia	-	-	-
8.	75	M	Brazil	Asthma CIHD	Ventolin Aerowent	-	-	-
9.	76	M	Romania	HTN	-	-	-	-
10.	73	M	Romania	HTN	Convertin	-	-	-

Average age was 74.9 ± 9.1 in group 1, 70.9 ± 7.9 in group 2 and 74.9 ± 2.5 in Group 3 ($p=0.21$). No significant effect was found in the age of onset of PD symptoms.

Two thirds of the subjects of Group 1 reported a short term earlier work in agriculture. In Group 2 there was no history of severe exposure, except that their place of residence and occupation are connected to agriculture, thus it is assumed that these subjects were chronically exposed to OP. There was no significant difference between Groups 1 and 2 with regards to progress and symptoms of the PD. The clinical evaluation seems to suggest that in Group 2, the expression of all 3 components of PD (bradikinesia, rigidity and tremor) was more prominent regarding patient decline in function.

Three participants of the study, all from Group 2, reported a family history of PD. All the patients received Dopical (Levidopa, Carbidopa).

The medications taken by the subjects have no extra epidermal or AChE inhibitory activity, and it is not unreasonable to assume that they would cause the PD symptoms . Details of the drugs constituents are shown in Table 6.

Table 6: Drugs and constituents

Chemical group	Drug	Constituents
H2 blocker	Gastro	Famotidine
L-Dopa +Carbidopa	Dopicar	Levodopa, Carbidopa
Beta blocker	Adalat	Propranolol
Dopamine agonist	Pergolide	Pergolide mesylate
Ca channel blocker	Norvasc	Amlodipine mesylate
Sedatives	Phenergane	Promethazine hydrochloride
Statins	Simovil	Simvastatine
Beta blocker	Deralin	Propranolol hydrochloride
NSAID	Cartia	Acetylsalicylic acid
Statins	Lipidal	Simvastatin
ACE-inhibitor	Captopril	Captopril
Biphosphonates	Fosalan	Alendronic acid
Antiepileptic	Tegretol	Carbamazepine
Neuroprotector	Selegiline	Selegiline hydrochloride

Vitamin	Evitol	Alpha Tocopheryl acetate(vit E)
Antidiabetic	Glibetic	Glibenclamide
Antiestrogen	Tamoxil	Tamoxifen citrate
ACE inhibitor	Capoten	Captopril
Dopamine agonist	Ropinirol	Ropinirol
ACE inhibitor	Convertin	Captopril
Beta blocker	Normiten	Atenolol
COMT inhibitor	Comtan	Entocapone
Dopamine agonist	Bromocriptine	Bromocriptine
Diuretics	Lasix	Furosemide
Ca channel blocker	Verapamil	Verapamil hydrochloride
Antiepileptic	Dilantin	Phenytoin
Adrenomimetic beta II	Ventolin	Salbutamol
Antimuscarinic	Aerowent	Ipratropium bromide
L-Dopa + carbidopa	Sinemet	Co-Carbidopa

The frequency of patient's complaints is shown in Table 7. There are no significant differences in the frequency of complaints about different body systems between rural and urban PD patients.

Table 7

	Urban PD patients (n=15)			Rural PD patients (n=15)			Healthy rural people (n=10)		
	slight	moderate	severe	slight	moderate	severe	slight	moderate	severe
General ill feeling	20		20	20	13.2		20		
Weakness	20	6.6	13.2	33	20		20		
Headache	40			6.6			20	10	
Muscle weakness	6.6	6.6	6.6	26.4	6.6	6.6			
Tremor	6.6		33	26.4	26.4	6.6			
Arthralgia	20		33	26.4	6.6	6.6		10	
Visual disturbances	40		6.6	20	13.2	33	10	30	
Night blindness	33			26.4		6.6			
Abdominal cramps	20	6.6		6.6	13.2	6.6			
Diarrhea	33							20	
Constipation	33		20	20	13.2	6.6	20	30	
Urinary retention	13.2			13.2			20		
Urinary urgency	13.2			13.2	6.6	6.6	30	20	
Vomiting	13.2			6.6	6.6		20		
Sialorrhea	13.2				6.6			20	
Dry mouth	13.2			20				20	
Rhinitis	13.2			6.6				10	
Chest pain	13.2				6.6		30		
Tachycardia	13.2				6.6				
Difficulty of concentration	20	6.6			13.2			20	
Nervousness	20			20	13.2			20	

B. Detection of polymorphisms

Amongst the 40 subjects studied for polymorphism in the *AChE* gene, there were 5 carriers of the HNF3-binding site four-nucleotide deletion, which were 1 from Group 1 and 4 from Group 2. There were no carriers of this polymorphism in Group 3.

This result is consistent with the frequency found in the general population of 1:26. In this study, the frequency is 1:6 in the exposed or non-exposed PD patients, and 1:4 in the chronically exposed PD patients (Group 2).

As in earlier studies, no homozygotes for this polymorphism were found, possibly because bearing two copies of this allele might be lethal. All 5 patients with this deletion were also carriers of haplotype Ytb. This indicates that there is linkage between these two polymorphisms, and likely common genomic origin. In addition, a third *AChE* polymorphism, P446 was found in 5 subjects, 4 heterozygotes and 1 homozygote, such that the idea of a common ancient origin of the haplotype is reinforced.

In 12 patients, from Groups 1 and 2, the L55M polymorphism of *PON1* was detected. And Q192R was also tested. There was no unequivocal linkage between *PON1* and *AChE*.

There was no correlation in age, sex, age of onset, ethnical origin and medical history between the carriers of the deletion mutation which participated. It is important to indicate that in Shapira [Shapira *et al.* (2000) *id ibid.*], there was one carrier of the *AChE* HNF3 deletion who was very sensitive to AChE inhibitors and another that had a history of recurring miscarriages. In the women carrying this deletion in the present study no miscarriages were reported, although the fertility age of most of them might have preceded exposure. In addition, it was found that out of five HNF3 carriers, three also carried this mutation in oral epithelial cells as well, excluding the possibility

15037/bc/02

that this was a somatic mutation in blood cells. The lack of mutation in the other 2 patients might be the result of technical difficulties regarding the identification of the mutation in the oral epithelial cells, the yield of which was rather low.

C. AChE and BuChE activities

Table 8 summarizes the results of serum enzymatic activity and the mutations. It is important to note that in the tested population, the number of possible haplotypes is 640 combinations, while in this study only four possible combinations were found, leading to the conclusion that there is a common genetic origin of the tested population.

Table 8: AChE and BChE activities in serum, protein concentration, and mutations found in patients' blood

No.	Protein conc. mg/ml	AChE activity nmol/mi n/ml	AChE activity nmol/min/ mg	BuChE activity nmol/mi n/ml	BuChE activity nmol/min/ mg	MUTATIONS			
						HNF	YTb	P446	PON1 (L55-M)
1	17.5	53.1	3.03	2955	168.8	-	-	-	-
2	22.4	29.4	1.3	2269	101.3	-	-	-	-
3	16.7	16	0.06	1038	62.1	-	-	-	+
4	15.5	22.4	1.45	1966	126.8	-	-	-	+
5	22.3	36.7	1.65	1594	71.4	-	-	-	-
6	16.6	74.6	4.49	722	43.4	-	-	-	-
7	17.6	60.3	3.4	2729	155	-	-	-	-
8	18.7	18.9	1	992	53.3	-	-	-	-
9	17.5	27.9	1.6	2072	118.4	+	+	+	+
10	12.2	32.1	2.63	1004	82.8	-	-	-	+
11	8.1	36.5	4.5	2006	247.6	-	-	-	+
12	11.7	35.2	3	2637	225.3	-	-	-	+
13	23.6	50.3	2.13	1379	58.4	-	-	-	+
14	23.4	30.6	1.3	1693	72.3	-	-	-	-
15	12.2	30.6	2.5	1140	93.4	-	-	-	-
16	24.5	27.5	1.12	1281	50.2	-	-	-	+
17	25.3	47.2	1.86	1443	57	-	-	-	-
18	24.6	64.1	2.6	2247	91.3	-	-	-	-
19	22.8	52.3	2.29	1948	85.4	-	-	-	-
20	22.8	59.7	2.62	2598	113.9	-	-	-	-
21	28	30.2	1	1598	57	+	+	+	+
22	28.4	57.5	2	1440	50.7	-	-	-	-
23	24	46.5	1.94	2165	90.2	-	-	-	-
24	26.2	31.4	1.2	1775	67.7	+	+	+	+
25	24.6	40.3	1.64	1337	54.3	+	+	+	+
26	18.3	21.7	1.18	559	30.5	+	+	+	+
27	56.2	39.6	0.7	5008	89.2	-	-	-	-
28	23	55.4	2.4	1369	59.5	-	-	-	-
29	46.5	54.2	1.16	2498	53.7	-	-	-	-
30	20.8	35.1	1.67	1147	55.1	-	-	-	-
31	27.9	59.4	2.12	6494	232.8	-	-	n.d.	n.d.
32	55.4	61.3	1.1	5821	105	-	-	n.d.	n.d.
33	28.4	121.2	4.27	6982	245.8	-	-	n.d.	n.d.
34	28.6	35.5	1.24	3953	138.2	-	-	n.d.	n.d.
35	35	43	1.23	1678	77.9	-	-	n.d.	n.d.
36	22.2	63.6	2.86	4224	190.2	-	-	n.d.	n.d.
37	2.28	37.9	1.66	135	59.2	-	-	n.d.	n.d.
38	35	34	0.97	4842	138.2	-	-	n.d.	n.d.
39	40.2	38	0.95	6706	166.8	-	-	n.d.	n.d.
40	32.8	61.6	1.87	5116	155.9	-	-	n.d.	n.d.
FREQUENCY OF MUTATION (%)						12.5	10	10	27.5

Abbreviations: n.d.=not done.

D. Differences in the AChE and BuChE activities

Table 9 shows the differences in the AChE and BuChE activities.

Table 9

	Urban PD patients (n=15)		Rural PD patients (n=15)		Healthy rural subjects (n=10)
	wt* (n=14)	carr** (n=1)	wt (n=11)	carr (n=4)	1.87±1.04
AChE activity nmole/min/mg	2.32±1.3	1.6	1.85±0.64	1.26±0.27	
BChE activity nmole/min/mg	111.5 ±64.8	n.d.118.4	72.3±22.1	52.8±15.7	151±61.19

Abbreviations: wt=non-carrier of the mutation; carr=carrier of the mutation. Results are expressed as mean \pm SD.

As shown in Tables 8 and 9 and in Figures 5 to 9, BuChE activity is higher in urban subjects than rural subjects, wherein $p=0.02$. This is possibly a result of the exposure to PO.

BuChE activity in rural PD patients carriers of the HNF3 polymorphism is not statistically different from BuChE activity in PD patients non-carriers, with no connection to the place of residence.

AChE activity in PD patients who are HNF3 carriers is about 50% lower than the activity in non-carrier, rural PD patients. Shapira (2000) reported an increase in AChE in erythrocytes of carriers of the ACHE promoter deletion [Shapira *et al.* (2000) *id ibid.*]. It is possible that the carriers of the mutations who are chronically exposed to OPs cannot increase AChE blood levels in response to exposure, and due to this failure of protection against stress they might be more sensitive to OP exposure and tend to develop a degenerative process under this exposure.

BuChE activity in Group 3 is higher than BuChE activity in PD patients both carriers and non-carriers of the HNF3 mutation. The differences are statistically significant, with $p=0.003$ for carriers and $p=0.002$ for non-carriers. This difference in BuChE activity in the two groups is surprising. Two possible explanations are envisaged. The control group subjects (Group 3) might have been less exposed to OPs, or alternatively, their liver metabolism is more active, leading to more BuChE production.

Example 2

Frequency of “HNF-polymorphism” on the *ACHE* promoter

Over one third of PD patients suffer cholinergic deficiencies [Soreq and Zakut, 1993]. Exposure to anti-AChEs, which causes AChE over-expression, is known to increase the risk for PD [Kaufer and Soreq, 1999]. Therefore, the inventors explored the possibility that the HNF₃ mutation, which activates ACHE gene expression, is also associated with an increased risk for PD. The results of this study indicate that this previously unforeseen hypothesis seems to be true.

The incidence of *ACHE* promoter polymorphism was tested in several groups of Israeli individuals, healthy and unhealthy. The latter included women with pregnancy complications, and older patients following stroke or Parkinson's Disease patients (Fig. 10).

Because of the small sample size, the frequency of the mutation in some of the groups must be considered a preliminary finding. The apparently higher incidence of the *ACHE* promoter polymorphism in elderly patients with Parkinson's Disease initiated further analysis into this potential correlation.

Figure 11 shows the analysis of the incidence of the HNF polymorphism in *ACHE* in PD patients, in particular those exposed to agricultural insecticides. Indeed PD patients presented a higher frequency of the HNF polymorphism.

The increase in frequency was especially significant in PD patients pre-exposed to agricultural insecticides.

Example 3

PD screen of *PON1* alleles in Israeli versus other populations

Table 10: Healthy population

<i>PON1</i> allele	Israel	Russia (Akhmedova <i>et al.</i> , 1999 ^a ; 2001 ^b)	Japan (Kondo <i>et al.</i> , 1998 ^c ; Suehiro <i>et al.</i> , 2000 ^d)
55L	0.61	0.69	0.94
55M	0.39	0.31	0.06
192Q	0.7	0.74	0.381
192R	0.3	0.26	0.691

^a[Akhmedova, S., Anisimov, S., Yakimovsky, A., and Schwartz, E. (1999). Gln --> Arg 191 polymorphism of paraoxonase and Parkinson's disease. *Hum Hered* 49, 178-180.

^b[Akhmedova *et al.* (2001) *id ibid.*]

^c[Kondo *et al.* (1998) *id ibid.*]

^d[Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumon, Y., Shindo, M., Tanaka, H., and Hashimoto, K. (2000). A polymorphism upstream from the human paraoxonase (*PON1*) gene and its association with *PON1* expression. *Atherosclerosis* 150, 295-298.]

Table 11: PD population

<i>PON1</i> allele	Israel (n=39)	Russia (Akhmedova <i>et al.</i> , 1999 ^a ; 2001 ^b)	Japan (Kondo <i>et al.</i> , 1998 ^c ; Suehiro <i>et al.</i> , 2000 ^d)
55L	0.54	0.57	-
55M	0.46	0.43	-
192Q	0.69	0.75	0.278
192R	0.31	0.25	0.722

^a[Akhmedova *et al.* (1999) *id ibid.*]^b[Akhmedova *et al.* (2001) *id ibid.*]^c[Kondo *et al.* (1998) *id ibid.*]^d[Suehiro *et al.* (2000) *id ibid.*]

Table 12: PD patients' genotype in the Israeli population

<i>PON1</i> allele	HNF carriers (n=5)	Non-carriers (n=39)
55L	0.5	0.54
55M	0.5	0.46
192Q	0.5	0.69
192R	0.5	0.31

Tables 10, 11 and 12 show the results of comparisons of the genotype presented by PD patients in Israel in comparison with Russia and Japan. The healthy population in Israel mimics the Russian and not the Japanese population with respect to the *PON1* polymorphism pattern. There are more L55, Q192 carriers than M55, R192 carriers.

Interestingly, PD population in Israel is also closer to the Russian one, as evidenced by the frequency of polymorphism in both positions 55 and 192.

The HNF mutation carriers among the Israeli PD patients have lower incidence of Q192 allele than healthy subjects (like the Japanese patients, distinct from the Russians).

The present results are still considered preliminary, since the sample size is relatively small.

Example 4

Study of the genotype of PD patients in Israel revealed a single haplotype which apparently spans over 10,000 Kb and includes both *PON1* and *ACHE* polymorphisms.

Table 13: Apparent linkage between *ACHE* and *PON1* polymorphisms

Patient No.	Haplotype	Personal details (medical history, sex, country of birth)
35	L/M - Q/R - het - A/B - het	OP exposure, M, 58, Argentina
40	L/M - Q/R - het - A/B - hom	OP exposure, M, 78, Russia
41	L/M - Q/R - het - A/B - het	OP exposure, M, 65, Russia
46	L/M - Q/R - het - A/B - het	OP exposure, M, 58, Argentina
1027	L/M - Q/R - het - A/B - het	OP exposure, M, 70, Morocco
1007	M/M - Q/Q - het - A/B - het	OP exposure, M, 42, n.k.

Note that in spite of the different ethnic origins, there is a common genotype that spans both the *ACHE* and *PON1* loci in all PD patients. Thus, the results suggest that risk-associated variants of *PON1* and *ACHE* may be genetically linked. Figure 12 shows the possible combinations of haplotypes that may exist in the general population. Interestingly, the haplotype including the *PON1* 55/192 mutations, and the *ACHE* HNF/yt/P446 polymorphisms, herein referred to as the "PD-susceptibility haplotype", is the predominant amongst PD patients, suggesting its relevance to causing the disease.

15037/bc/02

It is important to note that, as mentioned previously, both genes have variants that increase PD risk. Therefore, the combined inheritance of these variants may induce yet a larger risk to PD, and is being tested in a larger population

Claims:

1. Use of the "Parkinson Disease (PD)-susceptibility haplotype", as herein defined, as a tool for the prediction of PD risk and severity in a population and/or an individual.
2. A diagnostic method of predicting susceptibility to PD, based on the detection of the "PD-susceptibility haplotype", as herein defined, in an individual.
3. A method of screening for a genetic predisposition to PD, wherein said method involves the steps of:
 - (c) obtaining a blood sample from an individual to be screened;
 - (d) analyzing the DNA from the blood sample of (a) for the presence or absence of the "PD-susceptibility haplotype", as herein defined, by appropriate means;wherein the presence of the "PD-susceptibility haplotype" indicates a higher predisposition to PD, and the absence of the "PD-susceptibility haplotype" indicates a lower predisposition to PD, compared to a control.
4. A kit for screening for a genetic predisposition to PD, including
 - (a) means for collecting a blood sample;
 - (b) reagents for detecting the presence of the "PD-susceptibility haplotype".

לוצאטו את לוצאטו
LUZZATTO & LUZZATTO
By: *[Signature]*

15037/bc/02

Yissum Development Research Company of the Hebrew University of
Jerusalem/ Ben-Gurion University

1.....SHEETS
SHEET No.1.....




Figure 1

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University





Figure 2

15037/bc/02

Yissum Development Research Company of the Hebrew University of
Jerusalem/ Ben-Gurion University

12 SHEETS
SHEET No. 3

A.



B.

wt	GTGAGAATGGCTGCTGCTTCATAGACAGAGCAGCCCCGATGGCTGCTGGTGGCCATTGGT
Δ	GTGAGAATGGCTGCTGCTTCATAGACAGAGCAGCCCCGATGGCTGCTGGTGGCCATTGGT
wt	TTCGTTTGTTTTAT TGTTTGTT TCTTCTTTTTATTAGTT <u>TGTTTGTT</u> GTTGGTT
Δ	TTCGTTTGTTTTAT TGTT --- A TCTTCTTTTTATTAGTT <u>TGTTTGTT</u> GTTGGTT
wt	GGCTATTTCTAATGGTTATTTATTGATCGTATGCTAAAGAAGGGGTGGATTATTCTGA
Δ	GGCTATTTCTAATGGTTATTTATTGATCGTATGCTAAAGAAGGGGTGGATTATTCTGA
wt	GTTTCCAGAACAGAGGGTAGGAATTCCCAGAACTGAG
Δ	GTTTCCAGAACAGAGGGTAGGAATTCCCAGAACTGAG


Figure 3

15037/bc/02

Yissum Development Research Company of the Hebrew University of
Jerusalem/ Ben-Gurion University

12 SHEETS
SHEET No. 9

A.



B.




Figure 4

15037/bc/02

Yissum Development Research Company of the Hebrew University of
Jerusalem/ Ben-Gurion University

12 SHEETS
SHEET No. 5

BChE Activity in Urban and Rural Patients




Figure 5

15037/bc/02

Yissum Development Research Company of the Hebrew University of
Jerusalem/ Ben-Gurion University

.....12..... SHEETS
SHEET No.6.....




Figure 6

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University

.....12..... SHEETS
SHEET No.2....




Figure 7

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University

.....1/2.....SHEETS
SHEET No.8.....




Figure 8

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University

.....12..... SHEETS
SHEET No.9.....




Figure 9

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University

.....12..... SHEETS
SHEET No. 10.....




Figure 10

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University




Figure 11

15037/bc/02

Yissum Development Research Company of the Hebrew University of Jerusalem/ Ben-Gurion University




Figure 12

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.